Lilly Faces New Lawsuits Claiming Excess Marketing of Zyprexa
April 20 (Bloomberg) -- Eli Lilly & Co., which settled litigation over its Zyprexa drug for $700 million last year, faces thousands of new patient claims, three state lawsuits and government probes into marketing of the schizophrenia pill.
The new suits say, as the old ones did, that Indianapolis- based Lilly failed to warn that Zyprexa can cause diabetes and other illnesses. Patients also charge that Lilly improperly promoted Zyprexa, its top-selling drug, for uses not approved by regulators.
· Read The Full Depression Drugs, ADD & Depression Drugs Article From Bloomberg -->
·
Read All Depression, ADD & Psychiatric Drugs News Stories -->